Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADVM Adverum Biotechnologies	$2.54 -6.6%	$2.48	$1.78 ▼ $10.14	$56.82M	0.7	263,759 shs	65,761 shs
BVNRY Bavarian Nordic	$9.45 -0.7%	$8.75	$6.60 ▼ $14.60	$2.25B	1.36	2,172 shs	2,708 shs
KRYS Krystal Biotech	$148.17 -1.0%	$136.18	$122.80 ▼ $219.34	$4.33B	0.67	287,456 shs	267,497 shs
MESO Mesoblast	$11.11 +0.8%	$11.20	$5.78 ▼ $22.00	$1.41B	2.39	277,575 shs	242,362 shs
TWST Twist Bioscience	$38.03 -1.1%	$33.36	$27.12 ▼ $60.90	$2.30B	2.41	969,927 shs	679,091 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADVM Adverum Biotechnologies	+7.09%	+14.05%	-2.51%	-20.70%	-65.04%
BVNRY Bavarian Nordic	+4.39%	+7.69%	-0.10%	+27.27%	+5.31%
KRYS Krystal Biotech	+0.56%	+4.71%	+8.34%	-9.25%	-22.58%
MESO Mesoblast	+4.85%	+2.13%	-13.30%	+8.68%	+48.32%
TWST Twist Bioscience	-1.66%	+0.94%	+11.67%	-0.98%	-24.55%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADVM Adverum Biotechnologies	4.0813 of 5 stars	3.4	3.0	0.0	4.8	0.0	2.5	0.6
BVNRY Bavarian Nordic	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	4.5826 of 5 stars	3.5	1.0	0.0	4.7	2.9	2.5	1.9
MESO Mesoblast	1.8217 of 5 stars	3.5	1.0	0.0	0.0	1.8	0.8	0.6
TWST Twist Bioscience	3.9863 of 5 stars	3.4	2.0	0.0	4.4	2.6	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADVM Adverum Biotechnologies	2.80	Moderate Buy	$23.80	853.91% Upside
BVNRY Bavarian Nordic	0.00	N/A	N/A	N/A
KRYS Krystal Biotech	3.00	Buy	$213.75	44.51% Upside
MESO Mesoblast	3.00	Buy	$18.00	61.51% Upside
TWST Twist Bioscience	2.70	Moderate Buy	$50.40	32.30% Upside

Current Analyst Ratings Breakdown

Latest ADVM, TWST, KRYS, MESO, and BVNRY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/9/2025	KRYS Krystal Biotech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$155.00 ➝ $176.00
6/26/2025	ADVM Adverum Biotechnologies	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $12.00
6/24/2025	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$240.00
5/16/2025	KRYS Krystal Biotech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$215.00 ➝ $155.00
5/15/2025	ADVM Adverum Biotechnologies	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$5.00 ➝ $4.00
5/15/2025	ADVM Adverum Biotechnologies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $33.00
5/15/2025	ADVM Adverum Biotechnologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/7/2025	KRYS Krystal Biotech	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$195.00 ➝ $189.00
5/7/2025	KRYS Krystal Biotech	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$219.00 ➝ $219.00
5/6/2025	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$240.00 ➝ $240.00
5/6/2025	TWST Twist Bioscience	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$55.00 ➝ $48.00

(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADVM Adverum Biotechnologies	$1M	52.12	N/A	N/A	$3.40 per share	0.73
BVNRY Bavarian Nordic	$829.12M	2.70	$1.05 per share	9.01	$6.99 per share	1.35
KRYS Krystal Biotech	$290.52M	14.71	$4.61 per share	32.11	$32.90 per share	4.50
MESO Mesoblast	$5.90M	241.37	N/A	N/A	$4.21 per share	2.65
TWST Twist Bioscience	$312.97M	7.29	N/A	N/A	$8.07 per share	4.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADVM Adverum Biotechnologies	-$130.93M	-$6.40	N/A	N/A	N/A	N/A	-130.53%	-66.31%	8/11/2025 (Estimated)
BVNRY Bavarian Nordic	$143.26M	$0.80	11.81	9.00	N/A	21.11%	11.89%	9.32%	8/28/2025 (Estimated)
KRYS Krystal Biotech	$89.16M	$4.16	35.53	14.67	N/A	37.17%	14.64%	13.28%	8/4/2025 (Estimated)
MESO Mesoblast	-$87.96M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/29/2025 (Estimated)
TWST Twist Bioscience	-$208.73M	-$3.25	N/A	N/A	N/A	-54.98%	-33.48%	-25.34%	8/1/2025 (Estimated)

Latest ADVM, TWST, KRYS, MESO, and BVNRY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/4/2025	Q2 2025	KRYS Krystal Biotech	$1.20	N/A	N/A	N/A	$95.42 million	N/A
8/1/2025	Q3 2025	TWST Twist Bioscience	-$0.54	N/A	N/A	N/A	$95.52 million	N/A
5/9/2025	Q1 2025	BVNRY Bavarian Nordic	N/A	$0.13	N/A	$0.13	N/A	$189.89 million
5/6/2025	Q1 2025	KRYS Krystal Biotech	$1.38	$1.20	-$0.18	$1.20	$98.66 million	$88.18 million
5/5/2025	Q2 2025	TWST Twist Bioscience	-$0.56	-$0.66	-$0.10	-$0.66	$92.00 million	$92.79 million
4/15/2025	Q4 2024	ADVM Adverum Biotechnologies	-$1.34	-$1.96	-$0.62	-$1.96	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADVM Adverum Biotechnologies	N/A	N/A	N/A	N/A	N/A
BVNRY Bavarian Nordic	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	N/A	N/A	N/A	N/A	N/A
TWST Twist Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADVM Adverum Biotechnologies	N/A	3.57	3.57
BVNRY Bavarian Nordic	N/A	2.81	1.44
KRYS Krystal Biotech	N/A	9.65	9.27
MESO Mesoblast	0.22	0.96	0.63
TWST Twist Bioscience	0.03	4.51	4.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADVM Adverum Biotechnologies	48.17%
BVNRY Bavarian Nordic	N/A
KRYS Krystal Biotech	86.29%
MESO Mesoblast	1.43%
TWST Twist Bioscience	N/A

Insider Ownership

Company	Insider Ownership
ADVM Adverum Biotechnologies	6.00%
BVNRY Bavarian Nordic	N/A
KRYS Krystal Biotech	13.70%
MESO Mesoblast	18.80%
TWST Twist Bioscience	3.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADVM Adverum Biotechnologies	190	20.89 million	19.64 million	Optionable
BVNRY Bavarian Nordic	1,611	236.57 million	N/A	Not Optionable
KRYS Krystal Biotech	210	28.90 million	24.94 million	Optionable
MESO Mesoblast	80	127.78 million	103.76 million	Optionable
TWST Twist Bioscience	990	59.92 million	58.11 million	Optionable

ADVM, TWST, KRYS, MESO, and BVNRY Headlines

Recent News About These Companies

Twist Bioscience Corporation (NASDAQ:TWST) CFO Adam Laponis Sells 2,449 Shares

4 hours ago | marketbeat.com

Emily M. Leproust Sells 476 Shares of Twist Bioscience Corporation (NASDAQ:TWST) Stock

July 8 at 4:53 AM | insidertrades.com

Insider Selling: Twist Bioscience Corporation (NASDAQ:TWST) CEO Sells 476 Shares of Stock

July 7, 2025 | marketbeat.com

Twist Bioscience Expands Express Delivery Turnaround Time to All Gene Fragments Regardless of Format

July 7, 2025 | finance.yahoo.com

Wealth Enhancement Advisory Services LLC Makes New Investment in Twist Bioscience Corporation (NASDAQ:TWST)

July 7, 2025 | marketbeat.com

Twist Bioscience Corporation (NASDAQ:TWST) Given Consensus Recommendation of "Moderate Buy" by Brokerages

July 2, 2025 | americanbankingnews.com

Twist Bioscience Corporation (NASDAQ:TWST) Given Consensus Rating of "Moderate Buy" by Brokerages

July 2, 2025 | marketbeat.com

Twist Bioscience Corporation (NASDAQ:TWST) Shares Sold by Sumitomo Mitsui Trust Group Inc.

June 30, 2025 | marketbeat.com

Twist Bioscience Corporation (NASDAQ:TWST) SVP Sells $10,441.92 in Stock

June 25, 2025 | insidertrades.com

Insider Selling: Twist Bioscience Corporation (NASDAQ:TWST) SVP Sells 292 Shares of Stock

June 24, 2025 | marketbeat.com

Twist Bioscience Corporation (NASDAQ:TWST) CEO Emily M. Leproust Sells 1,678 Shares

June 24, 2025 | marketbeat.com

Twist and Element Biosciences Expands Pact for Sequencing Workflow Solutions

June 23, 2025 | insidermonkey.com

SG Americas Securities LLC Acquires New Holdings in Twist Bioscience Corporation (NASDAQ:TWST)

June 19, 2025 | marketbeat.com

Twist Bioscience (NASDAQ:TWST) Trading 7.2% Higher - Time to Buy?

June 18, 2025 | marketbeat.com

Here's Why We're Not At All Concerned With Twist Bioscience's (NASDAQ:TWST) Cash Burn Situation

June 16, 2025 | finance.yahoo.com

Twist Bioscience Co. (NASDAQ:TWST) Shares Acquired by GAMMA Investing LLC

June 16, 2025 | marketbeat.com

Twist Bioscience Co. (NASDAQ:TWST) CAO Robert F. Werner Sells 839 Shares

May 29, 2025 | insidertrades.com

Twist Bioscience Co. (NASDAQ:TWST) Insider Dennis Cho Sells 531 Shares

May 24, 2025 | insidertrades.com

Twist Bioscience to Present at William Blair 45th Annual Growth Stock Conference

May 15, 2025 | 01net.it0

Twist Bioscience Corporation (TWST): Among Nicholas J. Pritzker’s Stock Picks with Huge Upside Potential

May 9, 2025 | msn.com

Twist Bioscience Co. (NASDAQ:TWST) Insider Dennis Cho Sells 689 Shares

May 8, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADVM, TWST, KRYS, MESO, and BVNRY Company Descriptions

Adverum Biotechnologies NASDAQ:ADVM

$2.54 -0.18 (-6.62%)

Closing price 04:00 PM Eastern

Extended Trading

$2.50 -0.04 (-1.77%)

As of 05:02 PM Eastern

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Bavarian Nordic OTCMKTS:BVNRY

$9.45 -0.07 (-0.74%)

As of 09:30 AM Eastern

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Krystal Biotech NASDAQ:KRYS

$148.17 -1.57 (-1.05%)

Closing price 04:00 PM Eastern

Extended Trading

$150.57 +2.40 (+1.62%)

As of 07:55 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Mesoblast NASDAQ:MESO

$11.11 +0.09 (+0.82%)

Closing price 04:00 PM Eastern

Extended Trading

$11.11 0.00 (0.00%)

As of 07:57 PM Eastern

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Twist Bioscience NASDAQ:TWST

$38.03 -0.44 (-1.14%)

Closing price 04:00 PM Eastern

Extended Trading

$37.65 -0.38 (-1.00%)

As of 06:28 PM Eastern

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time